Quantcast
Last updated on April 16, 2014 at 14:39 EDT

Latest Amgen Stories

2013-08-30 16:23:25

THOUSAND OAKS, Calif., Aug. 30, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate at Citi's 8(th) Annual Biotech Conference on Tuesday, Sept. 3, 2013, in Boston, beginning at 2:00 p.m. Eastern Daylight Time. Scott Foraker, vice president and general manager of Biosimilars at Amgen, will participate in a panel at the conference entitled "Biosimilars: Risks & Opportunities - Looking at the Crystal Ball." Live audio of the presentation can be accessed from the Events...

2013-08-29 16:25:04

AUSTIN, Texas, Aug. 29, 2013 /PRNewswire/ -- XBiotech announced today that Dr. Fabrizio Bonanni has joined the Company as a member of the Board of Directors. Dr. Bonanni joins XBiotech after stepping down from Amgen this year where he ended his tenure as that Company's most senior officer in charge of operations. At Amgen, Dr. Bonanni held the position of Executive Vice President of Operations from 2007-2012, and between 1999-2007 held Senior Vice President positions in charge of...

2013-08-28 23:27:00

NWC Physicians praise Elan Pharmaceuticals for developing a vaccine that removes the buildup of beta-amyloid and plaque in the brain, restoring function without side effects in an 80 patient trial according to a recent report published in the Daily Mail*. (PRWEB) August 28, 2013 Research teams at the University of Edinburgh Medical School and University of Toronto Medical School report; "Not only were we able to clean up the brain tissue, but we also prevented the behavioral...

2013-08-28 08:27:22

CORAL SPRINGS, Florida, August 28, 2013 /PRNewswire/ -- FinancialNewsMedia.com issues news updates for today's leading healthcare companies: Bio-Solutions Corp. (OTCQB: BISU), Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX), MannKind Corporation (NASDAQ: MNKD), Amgen (NASDAQ: AMGN) and Accuray Incorporated (NASDAQ: ARAY). Bio-Solutions Corp. (BISU): Bio-Solutions Corp. Announces National Direct Response Marketing Campaign for Type2Defense(TM). Bio-Solutions today...

2013-08-27 16:24:31

THOUSAND OAKS, Calif., Aug. 27, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present new data on omecamtiv mecarbil, a small molecule cardiac myosin activator that is being studied for the treatment of heart failure in collaboration with Cytokinetics. Amgen will also present data on AMG 145, an investigational human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad"...

2013-08-26 20:22:25

SAN DIEGO and SAN FRANCISCO, Aug. 26, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the acquisition of Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) ("Onyx") by Amgen Inc. (NASDAQ: AMGN) ("Amgen"). On August 26, 2013, Amgen and Onyx announced that their boards of directors have unanimously approved a transaction under which Amgen will acquire all outstanding shares of Onyx for $125.00 per share in cash. The merger is expected to close at the...

2013-08-25 20:20:20

Attractive Addition to Amgen's Leading Oncology Portfolio and Pipeline THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 25, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash. Onyx...

2013-08-21 23:26:56

NWC physicians respond to a recent WPTV* report that fails to mention that the memory; mood and cognitive function impairments of Alzheimer’s may be reversed to a degree that is meaningful and life changing. (PRWEB) August 21, 2013 Implementing the treatment detailed in Perispinal etanercept: a New Therapeutic Paradigm in Neurology** by Dr. Tobinick can enable a severely impaired person needing full time assisted living care who is unable to recognize their own children or even count to...

2013-08-19 12:24:59

Company names J. Kevin Buchi President and Chief Executive Officer, Pete A. Meyers Chief Financial Officer, and Lesley Russell, MBChB, MRCP Chief Operating Officer MALVERN, Pa., Aug. 19, 2013 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule SMAC mimetic drugs to treat cancer, today announced the appointment of a new senior executive leadership team with the goal of accelerating the development of the company and its lead product...

2013-08-14 23:25:12

Neurological Wellness Center physicians respond to a recent survey finding 37% of stroke survivors develop depression and report the alleviation of depression is a predictable outcome of perispinally administered Enbrel treatment for stroke. (PRWEB) August 14, 2013 An estimated 700,000 people have a stroke in the United States each year, and approximately 37% of stroke survivors develop depression within 2 years according to survey published in NewsFix*. Several studies have shown that...